* Seeks injunction against distributing generic Allegra-D
* Files motion along with Sanofi-Aventis US unit
* Albany shares fall 1 pct
March 23 (Reuters) - Albany Molecular Research Inc AMRI.O along with Sanofi Aventis SA’s (SASY.PA) U.S. unit sought a preliminary injunction against India’s Dr Reddy’s Laboratories Ltd (REDY.BO) from distributing a copycat version of allergy drug Allegra-D.
The companies motion, filed in a federal court in New Jersey, comes as a response to the U.S. health regulators’ approval of Dr Reddy’s generic version on March 17.
In September last year, Albany Molecular, which provides drug discovery, development and manufacturing services, had sued the Indian generic drugmaker alleging infringement of patents related to the manufacturing process of the drug.
Sanofi-Aventis holds the patents on the drug. Shares of Albany Molecular were down 1 percent at $8.87 in midday trade Tuesday on Nasdaq, while American Depositary Shares of Dr Reddy’s were up 2.5 percent at $29.00 on the New York Stock Exchange. (Reporting by Vidya L Nathan in Bangalore; Editing by Gopakumar Warrier)